Shanghai Hile Bio-Technology 과거 수익 실적
과거 기준 확인 0/6
Shanghai Hile Bio-Technology has been growing earnings at an average annual rate of 30.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 2.8% per year.
주요 정보
30.2%
수익 성장률
46.1%
EPS 성장률
Pharmaceuticals 산업 성장 | 10.9% |
매출 성장률 | -2.8% |
자기자본 수익률 | -2.8% |
순이익 | -12.5% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
Shanghai Hile Bio-Technology 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 230 | -29 | 130 | 23 |
30 Jun 24 | 229 | -4 | 115 | 24 |
31 Mar 24 | 240 | 45 | 107 | 24 |
31 Dec 23 | 241 | 63 | 101 | 25 |
30 Sep 23 | 213 | 193 | 87 | 26 |
30 Jun 23 | 248 | 173 | 100 | 30 |
31 Mar 23 | 286 | 125 | 120 | 30 |
31 Dec 22 | 300 | 122 | 126 | 30 |
30 Sep 22 | 352 | 57 | 147 | 31 |
30 Jun 22 | 350 | 58 | 146 | 30 |
31 Mar 22 | 331 | 51 | 131 | 30 |
31 Dec 21 | 347 | 54 | 135 | 29 |
30 Sep 21 | 331 | 39 | 128 | 31 |
30 Jun 21 | 309 | 33 | 129 | 30 |
31 Mar 21 | 304 | 16 | 142 | 29 |
31 Dec 20 | 259 | 9 | 125 | 30 |
30 Sep 20 | 257 | -4 | 135 | 25 |
30 Jun 20 | 258 | -2 | 124 | 25 |
31 Mar 20 | 254 | 12 | 106 | 26 |
31 Dec 19 | 278 | 12 | 111 | 30 |
30 Sep 19 | 275 | -2 | 95 | 34 |
30 Jun 19 | 285 | 5 | 112 | 34 |
31 Mar 19 | 274 | 7 | 121 | 32 |
31 Dec 18 | 255 | 21 | 121 | 27 |
30 Sep 18 | 261 | 76 | 133 | 23 |
30 Jun 18 | 265 | 92 | 124 | 30 |
31 Mar 18 | 292 | 109 | 133 | 24 |
31 Dec 17 | 304 | 114 | 148 | 20 |
30 Sep 17 | 332 | 98 | 169 | 13 |
30 Jun 17 | 334 | 88 | 196 | 0 |
31 Mar 17 | 340 | 82 | 200 | 0 |
31 Dec 16 | 343 | 86 | 194 | 0 |
30 Sep 16 | 330 | 93 | 176 | 0 |
30 Jun 16 | 322 | 94 | 160 | 0 |
31 Mar 16 | 322 | 95 | 152 | 0 |
31 Dec 15 | 317 | 95 | 144 | 0 |
30 Sep 15 | 291 | 92 | 132 | 0 |
30 Jun 15 | 278 | 101 | 116 | 0 |
31 Mar 15 | 278 | 99 | 121 | 0 |
31 Dec 14 | 285 | 101 | 124 | 0 |
31 Dec 13 | 319 | 119 | 118 | 0 |
양질의 수익: 603718 is currently unprofitable.
이익 마진 증가: 603718 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 603718 is unprofitable, but has reduced losses over the past 5 years at a rate of 30.2% per year.
성장 가속화: Unable to compare 603718's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: 603718 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
자기자본 수익률
높은 ROE: 603718 has a negative Return on Equity (-2.82%), as it is currently unprofitable.